Frazier Life Sciences Management, L.P. Autolus Therapeutics PLC Transaction History
Frazier Life Sciences Management, L.P.
- $1.59 Billion
- Q1 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 4,623,324 shares of AUTL stock, worth $9.43 Million. This represents 0.45% of its overall portfolio holdings.
Number of Shares
4,623,324
Previous 4,623,324
-0.0%
Holding current value
$9.43 Million
Previous $10.9 Million
34.04%
% of portfolio
0.45%
Previous 0.65%
Shares
2 transactions
Others Institutions Holding AUTL
# of Institutions
99Shares Held
163MCall Options Held
0Put Options Held
88.3K-
Wellington Management Group LLP Boston, MA27.1MShares$55.3 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$41.8 Million0.14% of portfolio
-
Deep Track Capital, LP Greenwich, CT17.8MShares$36.4 Million0.97% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$33.9 Million97.79% of portfolio
-
Armistice Capital, LLC New York, NY11MShares$22.4 Million0.26% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $185M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...